Eligibility requirements

• Age: 50-80
• Sex:
• BMI: 17-40
• Medication: Inclusion Criteria: – Must have completed a primary vaccination series against COVID-19 with an authorised COVID-19 vaccine with receipt of last dose >8 weeks prior to enrolment Exclusion Criteria: – Use of COVID-19 prophalctic or treatment monoclonal antibodies/antibody cocktails within 90 days prior to enrolment – Receipt of any vaccine in the 4 weeks preceding the study vaccination and any influenza vaccine within 8 weeks prior to enrolment – Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to enrolment – Administration of immunoglobulins and/or any blood products within 3 months prior to enrolment – Active cancer (malignancy) therapy within 3 years prior to enrolment
• Medical History: Exclusion Criteria: – History of COVID-19 infection as confirmed by RAT or PCR test – less than 8 weeks prior to enrolment – Any history of anaphylaxis to any prior vaccine. – History of a serious reaction to a prior influenza vaccination or known allergy to constituents of influenza vaccines – including egg proteins or polysorbate 80 – History of Guillain-Barré Syndrome within 6 weeks following a previous influenza vaccine – Known disturbance of coagulation – History of myocarditis or pericarditis